CCR1，全稱為C-C motif chemokine receptor 1，別名包括CD191、CKR-1、MIP1aR等。該蛋白屬于β趨化因子受體家族，具有七次跨膜結(jié)構(gòu)，主要表達(dá)于多種免疫細(xì)胞表面，如單核細(xì)胞、T淋巴細(xì)胞、嗜酸性粒細(xì)胞等。CCR1的主要功能是介導(dǎo)免疫細(xì)胞的遷移和活化，參與炎癥反應(yīng)和免疫調(diào)節(jié)。它通過(guò)與多種趨化因子配體結(jié)合，如MIP-1α、RANTES、MCP-3等，激活下游信號(hào)通路，影響免疫細(xì)胞的遷移方向、粘附能力、活化和增殖。
CCR1與多種疾病的發(fā)生發(fā)展密切相關(guān)。在自身免疫性疾病中，如類風(fēng)濕性關(guān)節(jié)炎和克羅恩病，CCR1的過(guò)度活化會(huì)導(dǎo)致免疫細(xì)胞過(guò)度浸潤(rùn)和炎癥反應(yīng)，從而引發(fā)組織損傷和疾病癥狀。在腫瘤領(lǐng)域，CCR1的表達(dá)與腫瘤細(xì)胞的轉(zhuǎn)移和侵襲密切相關(guān)。研究表明，CCR1可以促進(jìn)腫瘤相關(guān)巨噬細(xì)胞的募集，幫助腫瘤細(xì)胞逃避免疫監(jiān)視，從而促進(jìn)腫瘤的進(jìn)展。此外，CCR1還與一些感染性疾病和神經(jīng)退行性疾病有關(guān)。
針對(duì)CCR1的藥物研發(fā)近年來(lái)逐漸受到關(guān)注。目前，已有一些CCR1拮抗劑進(jìn)入臨床試驗(yàn)階段，用于治療類風(fēng)濕性關(guān)節(jié)炎、哮喘等疾病。這些藥物通過(guò)抑制CCR1與配體的結(jié)合，或者阻斷下游信號(hào)通路的激活，從而減輕炎癥反應(yīng)和疾病癥狀。

熱銷產(chǎn)品

Recombinant Human C-C chemokine receptor type 1 (CCR1)-VLPs (Active) (CSB-MP004839HU)

驗(yàn)證數(shù)據(jù)

CSB-MP004839HU is detected by Mouse anti-6*His monoclonal antibody.

Activity
Measured by its binding ability in a functional ELISA. Immobilized Human CCR1 at 10 μg/ml can bind Anti-CCR1 recombinant antibody(CSB-RA004839MA1HU). The EC₅₀ is 9.690-10.94 ng/mL.The VLPs (CSB-MP3838) is negative control.

The purity of VLPs was greater than 90% as determined by SEC-HPLC

Recombinant Human C-C chemokine receptor type 1 (CCR1), partial (CSB-EP004839HU1)

驗(yàn)證數(shù)據(jù)

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

CCR1 Antibody (CSB-PA004839LA01HU)

驗(yàn)證數(shù)據(jù)

Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA004839LA01HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human kidney tissue using CSB-PA004839LA01HU at dilution of 1:100

Immunofluorescent analysis of U251 cells using CSB-PA004839LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)